SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-017018
Filing Date
2022-11-09
Accepted
2022-11-09 07:50:39
Documents
64
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q xlo-20220930x10q.htm   iXBRL 10-Q 2029566
2 EX-31.1 xlo-20220930xex31d1.htm EX-31.1 12174
3 EX-32.1 xlo-20220930xex32d1.htm EX-32.1 5491
  Complete submission text file 0001558370-22-017018.txt   6086037

Data Files

Seq Description Document Type Size
4 EX-101.SCH xlo-20220930.xsd EX-101.SCH 38766
5 EX-101.CAL xlo-20220930_cal.xml EX-101.CAL 40053
6 EX-101.DEF xlo-20220930_def.xml EX-101.DEF 135323
7 EX-101.LAB xlo-20220930_lab.xml EX-101.LAB 356469
8 EX-101.PRE xlo-20220930_pre.xml EX-101.PRE 269333
58 EXTRACTED XBRL INSTANCE DOCUMENT xlo-20220930x10q_htm.xml XML 847577
Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Filer) CIK: 0001840233 (see all company filings)

IRS No.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40925 | Film No.: 221370694
SIC: 2834 Pharmaceutical Preparations